Rui Pinheiro, Cláudia Braga, Gisela Santos, Maria R Bronze, Maria J Perry, Rui Moreira, Dora Brites, Ana S Falcão
Glioblastoma (GBM) is the most common and aggressive type of brain tumor in adults. The triazene Temozolomide (TMZ), an alkylating drug, is the classical chemotherapeutic agent for gliomas, but has been disappointing against the highly invasive and resistant nature of GBM. Hybrid compounds may open new horizons within this challenge. The multicomponent therapeutic strategy here used resides on a combination of two repurposing drugs acting by different but potentially synergistic mechanisms, improved efficacy, and lower resistance effects...
January 18, 2017: ACS Chemical Neuroscience